Champions Oncology (CSBR) vs Gain Therapeutics (GANX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Gain Therapeutics (GANX) has outperformed Champions Oncology (CSBR) over the past year, losing 22.0% versus a loss of 23.0%. Over five years, CSBR leads with a -50.6% price change compared with -76.7% for GANX. Gain Therapeutics is the larger company by market cap ($70.5 million vs $69.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | GANX |
|---|---|---|
| Share price | $4.98 | $1.62 |
| Market cap | $69.31M | $70.48M |
| 1-day change | +2.05% | -3.29% |
| YTD return | -27.93% | -49.84% |
| 1-year return | -23.03% | -21.98% |
| 5-year return | -50.60% | -76.73% |
| Forward P/E | 49.80 | — |
| EPS (TTM) | $-0.07 | $-0.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.31 | $4.34 |
| 52-week low | $4.59 | $1.53 |
| Distance from 52-week high | -40.07% | -62.79% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +345.82% |
| Average volume | 11.33K | 493.98K |
| Shares outstanding | 13.92M | 43.64M |
| Employees | 214 | 20 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Healthcare · Biotechnology · 214 employees
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Healthcare · Biotechnology · 20 employees
CSBR vs GANX FAQ
Which is bigger, Champions Oncology or Gain Therapeutics?
Gain Therapeutics (GANX) is larger, with a market capitalization of $70.48M compared with $69.31M for Champions Oncology (CSBR).
Which stock has performed better over the past year, CSBR or GANX?
GANX returned -21.98% over the past 12 months, compared with -23.03% for CSBR (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and Gain Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.